Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633642 | 0.80 | KIF11 (0.37) | PRSS1PRSS2PRSS3RECQLHDAC8 | |
| SCHEMBL536636 | 0.80 | PRSS1 (0.37) | PRSS1PRSS2PRSS3RECQLPLAU | |
| SCHEMBL3663320 | 0.73 | PTPN1 (0.47) | HPGDKMT2A | |
| SCHEMBL20857707 | 0.72 | MAOB (0.43) | HPGDKMT2A | |
| SCHEMBL2770254 | 0.71 | CA12 (0.51) | HPGDKMT2A | |
| SCHEMBL29875658 | 0.71 | CA2 (0.38) | PRSS1PRSS2PRSS3RECQLPRKCI | |
| SCHEMBL1045835 | 0.71 | CA2 (0.38) | PRSS1PRSS2PRSS3RECQLPRKCI | |
| SCHEMBL320863 | 0.70 | PRSS1 (0.56) | PRSS1PRSS2PRSS3HPGDPLAU | |
| SCHEMBL15705337 | 0.69 | GAA (0.37) | PRSS1PRSS2PRSS3PLAUHDAC8 | |
| SCHEMBL15633480 | 0.69 | GAA (0.37) | PRSS1PRSS2PRSS3PLAUHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722712-B2 | Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100199-A1 | SUBSTITUTED ARYL 1 ,2,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | PRSS1 2041/4885PRSS2 3823/4885PRSS3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.